Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 4/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | AMY2A | P04746 | 4/20 | 0.49 |
| ▸ | CD69 | Q07108 | 1/20 | 0.46 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.43 |
| ▸ | LGALS1 | P09382 | 1/20 | 0.43 |
| ▸ | LGALS7; LGALS7B | P47929 | 1/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29737502 | 1.00 | LGALS3 (0.58) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL20390677 | 0.98 | LGALS3 (0.55) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL29449498 | 0.97 | LGALS3 (0.54) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL13427334 | 0.96 | LGALS3 (0.54) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL20390694 | 0.94 | LGALS3 (0.52) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL20390676 | 0.94 | LGALS3 (0.51) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL16214756 | 0.93 | LGALS3 (0.50) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL30110430 | 0.92 | LGALS3 (0.51) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL29563784 | 0.92 | LGALS3 (0.58) | LGALS3LGALS8LGALS4AMY2ACD69 | |
| SCHEMBL29407990 | 0.92 | LGALS3 (0.56) | LGALS3LGALS8LGALS4AMY2ACD69 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | claimed |
| US-20240261420-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| US-20240115714-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-11 | — | — | US | disclosed |
| US-11766481-B2 | Glycan modified short interfering RNA | GANNA BIO, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766481-B2 | Glycan modified short interfering RNA | SNRPE, FUT6, ALG8 | LGALS3 142/4885LGALS8 65/4885LGALS4 183/4885 |
| US-20220387607-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885 |
| US-20240261420-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885 |
| US-20240115714-A1 | GLYCAN MODIFIED NUCLEIC ACIDS, METHODS OF PREPARATION, AND THERAPEUTIC USES | NSUN3, RNGTT, SIGLEC7 | LGALS3 94/4885LGALS8 78/4885LGALS4 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.